Want to receive updates for this keyword?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign UpAntiphospholipid Syndrome
• keyword#1
Carlos Tortosa, Oscar Cabrera-Marante, Manuel Serrano, José A Martínez-Flores, Dolores Pérez, David Lora, Luis Morillas, Estela Paz-Artal, José M Morales, Daniel Pleguezuelo, Antonio Serrano
BACKGROUND: The antiphospholipid syndrome (APS) is defined by simultaneous presence of vascular clinical events and antiphospholipid antibodies (aPL). The aPL considered as diagnostics are lupus anticoagulant and antibodies anticardiolipin (aCL) and anti-ß2 glycoprotein-I (aB2GP1). During recent years, IgA aB2GP1 antibodies have been associated with thrombotic events both in patients positive, and mainly negative for other aPL, however its value as a pro-thrombotic risk-factor in asymptomatic patients has not been well defined...
2017: PloS One
#2
D Vasylyev, L Chernobay, O Vasylieva, M Oliinyk, M Vashuk
Pathogenetic mechanisms of the development of antiphospholipid syndrome (APS) are considered in the article, which is the basis for the development of clinical manifestations and laboratory markers of APS. The modern literature data are analyzed, according to which the presence of antiphospholipid antibodies is a hypercoagulable background, and the formation of thrombi occurs under the influence of other allowing procoagulation factors. The classification of the main types of hereditary thrombophilia is given, which is the primary disorder, against the background of which an autoimmune thrombosis APS develops...
June 2017: Georgian Medical News
#3
Matthieu Million, Nathalie Bardin, Simon Bessis, Nadia Nouiakh, Charlaine Douliery, Sophie Edouard, Emmanouil Angelakis, Annick Bosseray, Olivier Epaulard, Stéphanie Branger, Bernard Chaudier, Karine Blanc-Laserre, Nicole Ferreira-Maldent, Elisa Demonchy, France Roblot, Jacques Reynes, Felix Djossou, Camelia Protopopescu, Patrizia Carrieri, Laurence Camoin-Jau, Jean-Louis Mege, Didier Raoult
Q fever is a neglected and potentially fatal disease. During acute Q fever, antiphospholipid antibodies are very prevalent and have been associated with fever, thrombocytopenia, acquired heart valve disease, and progression to chronic endocarditis. However, thrombosis, the main clinical criterion of the 2006 updated classification of the antiphospholipid syndrome, has not been assessed in this context. To test whether thrombosis is associated with antiphospholipid antibodies and whether the criteria for antiphospholipid syndrome can be met in patients with acute Q fever, we conducted a cross-sectional study at the French National Referral Center for Q fever...
July 2017: Medicine (Baltimore)
#4
Hilde Kelchtermans, Walid Chayouâ, Bas de Laat
The antiphospholipid syndrome (APS) is characterized by vascular thrombosis and/or pregnancy morbidity with the persistent presence of antiphospholipid antibodies (aPLs). Progress is being made in understanding the pathogenesis of the syndrome, but difficulties persist in the identification of patients at risk for thrombosis and/or pregnancy morbidity. Beta-2 glycoprotein I (β2GPI), a plasma protein consisting of five sushi domains, is thought to be the main antigenic target of aPLs. Antibodies recognizing domain I of β2GPI are predominantly present in patients with an elevated risk of thrombosis, whereas antidomain IV/V antibodies are found in nonthrombotic autoimmune diseases...
July 18, 2017: Seminars in Thrombosis and Hemostasis
#5
REVIEW
Shruti Chaturvedi, Keith R McCrae
PURPOSE OF REVIEW: Laboratory criteria for the classification of antiphospholipid syndrome include the detection of a lupus anticoagulant and/or anticardiolipin and anti-β2-glycoprotein I antibodies. However, the majority of patients who test positive in these assays do not have thrombosis. Current risk-stratification tools are largely limited to the antiphospholipid antibody profile and traditional thrombotic risk factors. RECENT FINDINGS: Novel biomarkers that correlate with disease activity and potentially provide insight into future clinical events include domain 1 specific anti-β2GPI antibodies, antibodies to other phospholipids or phospholipid/protein antigens (such as anti-PS/PT), and functional/biological assays such as thrombin generation, complement activation, levels of circulating microparticles, and annexin A5 resistance...
July 2017: Current Rheumatology Reports
#6
REVIEW
Roberto Giacomelli, Antonella Afeltra, Alessia Alunno, Chiara Baldini, Elena Bartoloni-Bocci, Onorina Berardicurti, Francesco Carubbi, Alberto Cauli, Ricard Cervera, Francesco Ciccia, Paola Cipriani, Fabrizio Conti, Salvatore De Vita, Paola Di Benedetto, Andrea Doria, Alexandros A Drosos, Ennio Giulio Favalli, Saviana Gandolfo, Mariele Gatto, Rosa Daniela Grembiale, Vasiliki Liakouli, Rik Lories, Ennio Lubrano, Claudio Lunardi, Domenico Paolo Emanuele Margiotta, Laura Massaro, Pierluigi Meroni, Antonia Minniti, Luca Navarini, Monica Pendolino, Federico Perosa, Jacques-Olivier Pers, Marcella Prete, Roberta Priori, Francesco Puppo, Luca Quartuccio, Amelia Ruffatti, Piero Ruscitti, Barbara Russo, Piercarlo Sarzi-Puttini, Yehuda Shoenfeld, George A Somarakis, Francesca Romana Spinelli, Elisa Tinazzi, Giovanni Triolo, Francesco Ursini, Gabriele Valentini, Guido Valesini, Serena Vettori, Claudio Vitali, Athanasios G Tzioufas
Autoimmune diseases are a complex set of diseases characterized by immune system activation and, although many progresses have been done in the last 15 years, several unmet needs in the management of these patients may be still identified. Recently, a panel of international Experts, divided in different working groups according to their clinical and scientific expertise, were asked to identify, debate and formulate a list of key unmet needs within the field of rheumatology, serving as a roadmap for research as well as support for clinicians...
July 10, 2017: Autoimmunity Reviews
#7
S Phansenee, R Sekararithi, P Jatavan, T Tongsong
Objective The objective of this paper is to compare adverse pregnancy outcomes between normal pregnancies and pregnancies with systemic lupus erythematosus (SLE), particularly focusing on uncomplicated SLE with remission. Methods A retrospective cohort study was conducted by accessing the Maternal-Fetal Medicine (MFM) Unit database and the full medical records of the women. The records of singleton pregnancies with SLE and no underlying disease were assigned as the study group and their medical records were reviewed...
January 1, 2017: Lupus
#8
Aliaksandr Trusau, Michael L Brit, Melinda R Mohr
No abstract text is available yet for this article.
July 11, 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
#9
Hiroyuki Nakamura, Kenji Oku, Olga Amengual, Kazumasa Ohmura, Yuichiro Fujieda, Masaru Kato, Toshiyuki Bohgaki, Shinsuke Yasuda, Tatsuya Atsumi
OBJECTIVE: The aim of this study was to assess the value of a combination of anti-beta2-glycoprotein I domain I antibodies (aDI) and phosphatidylserine-dependent antiprothrombin antibodies (aPS/PT) tests for the diagnosis of antiphospholipid syndrome (APS). METHODS: This cross-sectional study involved a cohort of the patients who visited our clinic from April 2005 to March 2013. IgG aDI, IgG aPS/PT, and IgM aPS/PT tests, together with criteria-defined antiphospholipid antibodies (aPL) tests, were performed in all patients...
July 7, 2017: Arthritis Care & Research
#10
Carlos Pérez-Sánchez, María Ángeles Aguirre, Patricia Ruiz-Limón, María Carmen Abalos-Aguilera, Yolanda Jiménez-Gómez, Iván Arias-de la Rosa, Antonio Rodriguez-Ariza, Lucía Fernández-Del Río, José Antonio Gonzalez-Reyes, Pedro Segui, Eduardo Collantes-Estévez, Nuria Barbarroja, Francisco Velasco, Savino Sciascia, Irene Cecchi, María José Cuadrado, José Manuel Villalba, Chary López-Pedrera
OBJECTIVE: Antiphospholipid syndrome (APS) leukocytes exhibit an oxidative perturbation, directly linked to alterations in mitochondrial dynamics and metabolism. This disturbance is related to the patients' prothrombotic status and can be prevented by in vitro treatment with coenzyme Q10. Our aim was to investigate short-term effects of in vivo ubiquinol (reduced coenzyme Q10[Qred]) supplementation on markers related to inflammation and thrombosis in APS through a prospective, randomized, crossover, placebo-controlled trial...
July 6, 2017: Arteriosclerosis, Thrombosis, and Vascular Biology
#11
REVIEW
Laura Ormesher, Louise E Simcox, Clare Tower, Ian A Greer
Clinicians increasingly investigate women for thrombophilias due to their associations with venous thromboembolism and placenta-mediated pregnancy complication. These associations, however, are modest and based largely on retrospective data from studies with heterogeneous classifications and populations, leading to discordance between evidence and guidelines. Current evidence suggests a contributory rather than causative role for thrombophilia in placenta-mediated pregnancy complication and venous thromboembolism...
June 2017: Obstetric Medicine
#12
Nobuhiko Kobayashi, Yoshiyuki Ogawa, Kunio Yanagisawa, Takuma Ishizaki, Hideki Uchiumi, Nobuaki Suzuki, Tadashi Matsushita, Akitada Ichinose, Hiroshi Handa
Acquired von Willebrand syndrome (AvWS) is a rare bleeding disorder with laboratory findings resembling those of congenital von Willebrand disease. AvWS usually occurs in association with a variety of underlying disorders, such as lymphoproliferative disease or cardiovascular disease, but autoimmune AvWS is very rare. We now describe the case of a 42-year-old woman with autoimmune AvWS with concurrent antiphospholipid syndrome (APS). The patient was suffering from epistaxis and menorrhagia from few years prior to referral...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
#13
Daisuke Kudo, Misayo Shimizu, Akihiro Kuroda, Takuya Suyama, Atsushi Shinagawa, Syusaku Ito
A 66-year-old male underwent prednisolone (PSL) therapy of 13 mg/day for rheumatoid arthritis (RA). Antiphospholipid antibody syndrome, neutrophilic dermatosis (ND), and myelodysplastic syndrome (MDS) developed. Treatment of MDS required red cell concentrate transfusion, and second courses of azacitidine therapy (75 mg/m(2) daily, intravenous injection for 7 consecutive days) led to hematologic remission. Furthermore, ND improved early after the start of azacitidine therapy, making it possible to decrease the dose of PSL...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
#14
M B Urowitz, Konstantinos Tselios
BACKGROUND: Systemic lupus erythematosus (SLE) is characterized by various clinical manifestations and immunologic abnormalities. Among clinical manifestations, cardiovascular and respiratory system involvement is increasingly recognized as critical for patients' prognosis. OBJECTIVE: Heart involvement, most commonly presents with pericarditis. However, valvular disease and less often myocarditis may be detected. METHOD: Accelerated atherosclerosis is currently considered as one of the most important co-morbidities of SLE with cardiovascular events being one of the leading causes of death at relatively young ages...
July 4, 2017: Current Rheumatology Reviews
#15
Giorgia Grosso, Anna Vikerfors, Barry Woodhams, Mariette Adam, Katarina Bremme, Margareta Holmström, Anna Ågren, Anna Eelde, Maria Bruzelius, Elisabet Svenungsson, Aleksandra Antovic
BACKGROUND: Thrombosis and complement activation are pathogenic features of antiphospholipid syndrome (APS). Their molecular link is Plasma carboxypeptidase-B, also known as thrombin activatable fibrinolysis inhibitor (TAFIa), which plays a dual role: anti-fibrinolytic, by cleaving carboxyl-terminal lysine residues from partially degraded fibrin, and anti-inflammatory, by downregulating complement anaphylatoxins C3a and C5a. AIM: To investigate the levels of TAFI (proenzyme) and TAFIa (active enzyme) in relation to complement activation, fibrin clot permeability and fibrinolytic function in clinical and immunological subsets of 52 APS patients and 15 controls...
June 24, 2017: Thrombosis Research
#16
Fariborz Mobarrez, Iva Gunnarsson, Elisabet Svenungsson
BACKGROUND: Antiphospholipid antibodies (aPL) together with thrombosis and/or pregnancy morbidities characterize the antiphospholipid syndrome. β2-glycoprotein-I (β2 GPI), the most important antigen for aPL, is a scavenger molecule that specifically binds to phosphatidylserine (PS), expressed on microparticles (MPs). OBJECTIVES: We evaluated β2 GPI-expressing MPs in patients with systemic lupus erythematosus (SLE) stratified for aPL status, and healthy controls...
July 1, 2017: Journal of Thrombosis and Haemostasis: JTH
#17
Elizabeth Papalardo, Zurina Romay-Penabad, Rohan Willis, Premkumar Christadoss, Ana Laura Carrera-Marin, Elba Reyes-Maldonado, Rajani Rudrangi, Silvana Alfieri-Papalardo, Ethel Garcia-Latorre, Miri Blank, Silvia Pierangeli, Allan R Brasier, Emilio B Gonzalez
OBJECTIVE: Both environmental and genetic factors are important in antiphospholipid antibody(aPL) development in antiphospholipid syndrome(APS). Currently, the only available data on predisposing genetic factors have been obtained from epidemiological studies without mechanistic evidence. Therefore, we studied the influence of Major Histocompatibility Complex Class II(MHC-II) alleles on the production of aPL in an APS mouse model. METHODS: Three groups of mice: MHC-II deficient (MHC-II(-/-) ) mice, MHC-II(-/-) mice transgenic for human DQ6, DQ8 or DR4 alleles and their corresponding wild-type(WT) strains were each immunized, half with human β2 glycoprotein-I(β2 GPI) and the other half with control ovalbumin(OA) protein...
June 30, 2017: Arthritis & Rheumatology
#18
Ryo Hisada, Masaru Kato, Eri Sugawara, Yuichiro Fujieda, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Shinsuke Yasuda, Tatsuya Atsumi
BACKGROUND: Thrombocytopenia is a non-criteria clinical manifestation of antiphospholipid syndrome (APS). However, it remains to be elucidated whether thrombocytopenia increases thrombotic risk in antiphospholipid antibody (aPL) carriers. OBJECTIVES: To investigate the impact of platelet count in terms of predicting thrombotic events in aPL carriers and to stratify the thrombotic risk by combining platelet count and antiphospholipid score (aPL-S), which represents a quantification of aPL varieties and titres PATIENTS/METHODS: A single centre retrospective, longitudinal study comprising 953 consecutive patients who were suspected to have autoimmune disease between January 2002 and December 2006...
June 29, 2017: Journal of Thrombosis and Haemostasis: JTH
#19
Dosing considerations in the use of the direct oral anticoagulants in the antiphospholipid syndrome.
J R Schofield, K Hassell
WHAT IS KNOWN AND OBJECTIVES: At least four prospective trials have been initiated investigating the direct oral anticoagulants in the antiphospholipid syndrome. Preliminary reports have supported their use in patients with a history of venous thrombosis and a target INR of 2-3, but there have also been reports of failure of these agents in the antiphospholipid syndrome. The objective is to present a case report that illustrates there may be important dosing issues when considering the use of these agents in patients with the antiphospholipid syndrome...
June 27, 2017: Journal of Clinical Pharmacy and Therapeutics
#20
Miwa Matsuda, Aiko Sasaki, Keiko Shimizu, Yasuhiko Kamada, Soichi Noguchi, Yuji Hiramatsu, Mikiya Nakatsuka
Vascular dysfunction has been reported in women with recurrent pregnancy loss (RPL). We investigated the severity of vascular dysfunction in non-pregnant women with RPL and its correlation with anti-heat shock protein (HSP) antibodies that are known to induce arteriosclerosis. We measured the serum anti-HSP60 antibodies, anti-HSP70 antibodies, and anti-phospholipid antibodies (APA) in 68 women with RPL and 29 healthy controls. Among the women with RPL, 14 had a diagnosis of antiphospholipid syndrome (APS), and in the remaining 54, the causes for RPL were unexplained...
June 2017: Acta Medica Okayama
Fetching more papers... 
